MedTrace Logo

Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma

NCT02986451 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2018-08-14

No results posted yet for this study

Summary

This phase II study investigating the efficacy and safety of a combination of biaxin,lenalidomide and dexamethasone in subjects with relapsed/refractory MM.

Conditions

  • Relapse/Refractory Multiple Myeloma

Interventions

DRUG

clarithromycin

Clarithromycin 500mg PO twice daily on days 1-28 for a 28-day cycle.

DRUG

Lenalidomide

Lenalidomide 25mg PO daily on days 1-21 of a 28-day cycle

DRUG

Dexamethasone

Dexamethasone 40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle.

Sponsors & Collaborators

  • China Food and Drug Administration

    collaborator OTHER_GOV

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • zhongjun xia, MD. · hematological oncology department

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2018-12-31
Completion
2019-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02986451 on ClinicalTrials.gov